Literature DB >> 10077623

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

W W Overwijk1, D S Lee, D R Surman, K R Irvine, C E Touloukian, C C Chan, M W Carroll, B Moss, S A Rosenberg, N P Restifo.   

Abstract

Many human and mouse tumor antigens are normal, nonmutated tissue differentiation antigens. Consequently, immunization with these "self" antigens could induce autoimmunity. When we tried to induce immune responses to five mouse melanocyte differentiation antigens, gp100, MART-1, tyrosinase, and tyrosinase-related proteins (TRP) 1 and TRP-2, we observed striking depigmentation and melanocyte destruction only in the skin of mice inoculated with a vaccinia virus encoding mouse TRP-1. These mice rejected a lethal challenge of B16 melanoma, indicating the immune response against TRP-1 could destroy both normal and malignant melanocytes. Cytotoxic T lymphocytes specific for TRP-1 could not be detected in depigmented mice, but high titers of IgG anti-TRP-1 antibodies were present. Experiments with knockout mice revealed an absolute dependence on major histocompatibility complex class II, but not major histocompatibility complex class I, for the induction of both vitiligo and tumor protection. Together, these results suggest that the deliberate induction of self-reactivity using a recombinant viral vector can lead to tumor destruction, and that in this model, CD4(+) T lymphocytes are an integral part of this process. Vaccine strategies targeting tissue differentiation antigens may be valuable in cancers arising from nonessential cells and organs such as melanocytes, prostate, testis, breast, and ovary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077623      PMCID: PMC15881          DOI: 10.1073/pnas.96.6.2982

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Immunity to methylcholanthrene-induced sarcomas.

Authors:  R T PREHN; J M MAIN
Journal:  J Natl Cancer Inst       Date:  1957-06       Impact factor: 13.506

2.  Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice.

Authors:  M J Grusby; R S Johnson; V E Papaioannou; L H Glimcher
Journal:  Science       Date:  1991-09-20       Impact factor: 47.728

3.  Tumor immunity and autoimmunity induced by immunization with homologous DNA.

Authors:  L W Weber; W B Bowne; J D Wolchok; R Srinivasan; J Qin; Y Moroi; R Clynes; P Song; J J Lewis; A N Houghton
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

4.  Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells.

Authors:  M Zijlstra; M Bix; N E Simister; J M Loring; D H Raulet; R Jaenisch
Journal:  Nature       Date:  1990-04-19       Impact factor: 49.962

5.  Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis.

Authors:  R H Whitham; D N Bourdette; G A Hashim; R M Herndon; R C Ilg; A A Vandenbark; H Offner
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

6.  Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes.

Authors:  R J Barth; S N Bock; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

7.  A second tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus.

Authors:  I J Jackson; D M Chambers; K Tsukamoto; N G Copeland; D J Gilbert; N A Jenkins; V Hearing
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

8.  Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis.

Authors:  D Olivares-Villagómez; Y Wang; J J Lafaille
Journal:  J Exp Med       Date:  1998-11-16       Impact factor: 14.307

9.  Antibodies to normal human melanocytes in vitiligo.

Authors:  G K Naughton; M Eisinger; J C Bystryn
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

10.  CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.

Authors:  A M Thornton; E M Shevach
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  99 in total

1.  Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.

Authors:  G Zeng; C E Touloukian; X Wang; N P Restifo; S A Rosenberg; R F Wang
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

2.  Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.

Authors:  C E Touloukian; W W Leitner; P F Robbins; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

3.  Progress in cancer vaccines by enhanced self-presentation.

Authors:  S R Riddell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 4.  Hierarchy, tolerance, and dominance in the antitumor T-cell response.

Authors:  N P Restifo
Journal:  J Immunother       Date:  2001 May-Jun       Impact factor: 4.456

Review 5.  Autologous and allogeneic high-dose therapy for melanoma.

Authors:  K A Margolin
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

6.  Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.

Authors:  Paul F Robbins; Mona El-Gamil; Yong F Li; Gang Zeng; Mark Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

7.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

Review 8.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 9.  Regulation of tumour immunity by CD25+ T cells.

Authors:  Awen Gallimore; Shimon Sakaguchi
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

10.  Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.

Authors:  Christopher E Touloukian; Wolfgang W Leitner; Paul F Robbins; Yong F Li; Xiaoqiang Kang; Rejean Lapointe; Patrick Hwu; Steven A Rosenberg; Nicholas P Restifo
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.